Antipsychotic-induced weight gain and metabolic effects show diurnal dependence and are reversible with time restricted feeding.
Journal
Schizophrenia (Heidelberg, Germany)
ISSN: 2754-6993
Titre abrégé: Schizophrenia (Heidelb)
Pays: Germany
ID NLM: 9918367987006676
Informations de publication
Date de publication:
30 Aug 2022
30 Aug 2022
Historique:
received:
14
06
2022
accepted:
08
08
2022
entrez:
30
8
2022
pubmed:
31
8
2022
medline:
31
8
2022
Statut:
epublish
Résumé
Antipsychotic drugs (AP) are highly efficacious treatments for psychiatric disorders but are associated with significant metabolic side-effects. The circadian clock maintains metabolic homeostasis by sustaining daily rhythms in feeding, fasting and hormone regulation but how circadian rhythms interact with AP and its associated metabolic side-effects is not well-known. We hypothesized that time of AP dosing impacts the development of metabolic side-effects. Weight gain and metabolic side-effects were compared in C57Bl/6 mice and humans dosed with APs in either the morning or evening. In mice, AP dosing at the start of the light cycle/rest period (AM) resulted in significant increase in food intake and weight gain compared with equivalent dose before the onset of darkness/active period (PM). Time of AP dosing also impacted circadian gene expression, metabolic hormones and inflammatory pathways and their diurnal expression patterns. We also conducted a retrospective examination of weight and metabolic outcomes in patients who received risperidone (RIS) for the treatment of serious mental illness and observed a significant association between time of dosing and severity of RIS-induced metabolic side-effects. Time restricted feeding (TRF) has been shown in both mouse and some human studies to be an effective therapeutic intervention against obesity and metabolic disease. We demonstrate, for the first time, that TRF is an effective intervention to reduce AP-induced metabolic side effects in mice. These studies identify highly effective and translatable interventions with potential to mitigate AP-induced metabolic side effects.
Identifiants
pubmed: 36042214
doi: 10.1038/s41537-022-00276-2
pii: 10.1038/s41537-022-00276-2
pmc: PMC9427943
doi:
Types de publication
Journal Article
Langues
eng
Pagination
70Subventions
Organisme : BLRD VA
ID : I01 BX003431
Pays : United States
Organisme : Department of Veterans Affairs | Veterans Affairs San Diego Healthcare System (VA San Diego Healthcare System)
ID : BX003431
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases)
ID : R01DK117872
Informations de copyright
© 2022. The Author(s).
Références
Verhaegen, A. A. & Van Gaal, L. F. Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options. J. Endocrinol. Investig. 40, 1165–1174 (2017).
doi: 10.1007/s40618-017-0719-6
Laursen, T. M., Munk-Olsen, T., Nordentoft, M. & Mortensen, P. B. Increased mortality among patients admitted with major psychiatric disorders: a register-based study comparing mortality in unipolar depressive disorder, bipolar affective disorder, schizoaffective disorder, and schizophrenia. J. Clin. Psychiatry 68, 899–907 (2007).
pubmed: 17592915
doi: 10.4088/JCP.v68n0612
Mukherjee, S. et al. Understanding the effects of antipsychotics on appetite control. Front. Nutr. 8, 815456 (2021).
pubmed: 35047549
doi: 10.3389/fnut.2021.815456
Goncalves, P., Araujo, J. R. & Martel, F. Antipsychotics-induced metabolic alterations: focus on adipose tissue and molecular mechanisms. Eur. Neuropsychopharmacol. 25, 1–16 (2015).
pubmed: 25523882
doi: 10.1016/j.euroneuro.2014.11.008
Li, Y. et al. Berberine alleviates olanzapine-induced adipogenesis via the AMPKalpha-SREBP pathway in 3T3-L1 cells. Int. J. Mol. Sci 17, 1865 (2016).
pmcid: 5133865
doi: 10.3390/ijms17111865
Perez-Gomez, A. et al. A phenotypic Caenorhabditis elegans screen identifies a selective suppressor of antipsychotic-induced hyperphagia. Nat. Commun. 9, 5272 (2018).
pubmed: 30532051
pmcid: 6288085
doi: 10.1038/s41467-018-07684-y
Baptista, T. et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can. J. Psychiatry 51, 192–196 (2006).
pubmed: 16618011
doi: 10.1177/070674370605100310
Deng, C., Lian, J., Pai, N. & Huang, X. F. Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. J. Psychopharmacol. 26, 1271–1279 (2012).
pubmed: 22695490
doi: 10.1177/0269881112449396
Mehta, V. S. & Ram, D. Efficacy of ranitidine in olanzapine-induced weight gain: a dose-response study. Early Interv. Psychiatry 10, 522–527 (2016).
pubmed: 25529756
doi: 10.1111/eip.12205
Silverman, B. L. et al. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. Schizophr. Res. 195, 245–251 (2018).
pubmed: 29158012
doi: 10.1016/j.schres.2017.10.014
Stenvers, D. J., Scheer, F., Schrauwen, P., la Fleur, S. E. & Kalsbeek, A. Circadian clocks and insulin resistance. Nat. Rev. Endocrinol. 15, 75–89 (2019).
pubmed: 30531917
doi: 10.1038/s41574-018-0122-1
Chaix, A., Lin, T., Le, H. D., Chang, M. W. & Panda, S. Time-restricted feeding prevents obesity and metabolic syndrome in mice lacking a circadian clock. Cell Metabol. 29, 303–319.e304 (2019).
doi: 10.1016/j.cmet.2018.08.004
Wang, J. B. et al. Timing of energy intake during the day is associated with the risk of obesity in adults. J. Hum. Nutr. Diet 27, 255–262 (2014).
pubmed: 23808897
doi: 10.1111/jhn.12141
Arble, D. M., Bass, J., Laposky, A. D., Vitaterna, M. H. & Turek, F. W. Circadian timing of food intake contributes to weight gain. Obesity 17, 2100–2102 (2009).
pubmed: 19730426
doi: 10.1038/oby.2009.264
Duncan, M. J. et al. Restricting feeding to the active phase in middle-aged mice attenuates adverse metabolic effects of a high-fat diet. Physiol. Behav. 167, 1–9 (2016).
pubmed: 27586251
doi: 10.1016/j.physbeh.2016.08.027
Hatori, M. et al. Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. Cell Metabol. 15, 848–860 (2012).
doi: 10.1016/j.cmet.2012.04.019
Prasad, M. et al. A smartphone intervention to promote time restricted eating reduces body weight and blood pressure in adults with overweight and obesity: a pilot study. Nutrients 13, 2148 (2021).
pubmed: 34201442
pmcid: 8308240
doi: 10.3390/nu13072148
Sutton, E. F. et al. Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. Cell Metabol. 27, 1212–1221.e1213 (2018).
doi: 10.1016/j.cmet.2018.04.010
Pellegrini, M. et al. Effects of time-restricted feeding on body weight and metabolism. A systematic review and meta-analysis. Rev. Endocr. Metab. Disord. 21, 17–33 (2020).
pubmed: 31808043
doi: 10.1007/s11154-019-09524-w
Romo-Nava, F. et al. Olanzapine-induced early cardiovascular effects are mediated by the biological clock and prevented by melatonin. J. Pineal. Res. 62, e12402 (2017).
doi: 10.1111/jpi.12402
Viyoch, J. et al. Effect of haloperidol on mPer1 gene expression in mouse suprachiasmatic nuclei. J. Biol. Chem. 280, 6309–6315 (2005).
pubmed: 15590637
doi: 10.1074/jbc.M411704200
Romo-Nava, F. et al. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord. 16, 410–421 (2014).
pubmed: 24636483
doi: 10.1111/bdi.12196
Chipchura, D. A., Freyberg, Z., Edwards, C., Leckband, S. G. & McCarthy, M. J. Does the time of drug administration alter the metabolic risk of aripiprazole? Front. Psychiatry 9, 494 (2018).
pubmed: 30364286
pmcid: 6193090
doi: 10.3389/fpsyt.2018.00494
Kapse, S. et al. Effect of a dosing-time on quetiapine-induced acute hyperglycemia in mice. J. Pharmacol. Sci. 133, 139–145 (2017).
pubmed: 28279595
doi: 10.1016/j.jphs.2017.02.008
Shamshoum, H., Medak, K. D., McKie, G. L., Hahn, M. K. & Wright, D. C. Fasting or the short-term consumption of a ketogenic diet protects against antipsychotic-induced hyperglycaemia in mice. J. Physiol. 600, 2713–2728 (2022).
pubmed: 35507699
doi: 10.1113/JP282922
Wei, H. et al. Dopamine D2 receptor signaling modulates pancreatic beta cell circadian rhythms. Psychoneuroendocrinology 113, 104551 (2020).
pubmed: 31884319
doi: 10.1016/j.psyneuen.2019.104551
Bak, M., Fransen, A., Janssen, J., van Os, J. & Drukker, M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One 9, e94112 (2014).
pubmed: 24763306
pmcid: 3998960
doi: 10.1371/journal.pone.0094112
Komossa, K. et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 3, CD006654 (2010).
Komossa, K. et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 1, CD006626 (2011).
(AHRQ) AfHRaQ. ClinCalc DrugStats database version 21.1 (Medical Expenditure Panel Survey (MEPS), Rockville, MD, 2008–2018).
Zapata, R. C., Zhang, D., Chaudry, B., Osborn, O. Self-administration of drugs in mouse models of feeding and obesity. J. Visual. Exp. (2021).
Halfdanarson, O. et al. International trends in antipsychotic use: a study in 16 countries, 2005–2014. Eur. Neuropsychopharmacol. 27, 1064–1076 (2017).
pubmed: 28755801
doi: 10.1016/j.euroneuro.2017.07.001
Zapata, R. C. et al. Conserved immunomodulatory transcriptional networks underlie antipsychotic-induced weight gain. Transl. Psychiatry 11, 405 (2021).
pubmed: 34294678
pmcid: 8296828
doi: 10.1038/s41398-021-01528-y
Scheiermann, C., Gibbs, J., Ince, L. & Loudon, A. Clocking in to immunity. Nat. Rev. Immunol. 18, 423–437 (2018).
pubmed: 29662121
doi: 10.1038/s41577-018-0008-4
Wilkinson, M. J. et al. Ten-hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome. Cell Metabol. 31, 92–104.e105 (2020).
doi: 10.1016/j.cmet.2019.11.004
Kettner, N. M. et al. Circadian dysfunction induces leptin resistance in mice. Cell Metabol. 22, 448–459 (2015).
doi: 10.1016/j.cmet.2015.06.005
Adlanmerini, M. et al. Hypothalamic REV-ERB nuclear receptors control diurnal food intake and leptin sensitivity in dietinduced obese mice. J. Clin. Invest. 131, e140424 (2021).
pmcid: 7773391
doi: 10.1172/JCI140424
Brown, S. A., Zumbrunn, G., Fleury-Olela, F., Preitner, N. & Schibler, U. Rhythms of mammalian body temperature can sustain peripheral circadian clocks. Curr. Biol. 12, 1574–1583 (2002).
pubmed: 12372249
doi: 10.1016/S0960-9822(02)01145-4
Petrenko, V. et al. In pancreatic islets from type 2 diabetes patients, the dampened circadian oscillators lead to reduced insulin and glucagon exocytosis. Proc. Natl Acad. Sci. USA 117, 2484–2495 (2020).
pubmed: 31964806
pmcid: 7007532
doi: 10.1073/pnas.1916539117
Petrenko, V. et al. Pancreatic alpha- and beta-cellular clocks have distinct molecular properties and impact on islet hormone secretion and gene expression. Genes Dev. 31, 383–398 (2017).
pubmed: 28275001
pmcid: 5358758
doi: 10.1101/gad.290379.116
Perelis, M. et al. Pancreatic beta cell enhancers regulate rhythmic transcription of genes controlling insulin secretion. Science 350, aac4250 (2015).
pubmed: 26542580
pmcid: 4669216
doi: 10.1126/science.aac4250
Morris, C. J. et al. Endogenous circadian system and circadian misalignment impact glucose tolerance via separate mechanisms in humans. Proc. Natl Acad. Sci. USA 112, E2225–2234 (2015).
pubmed: 25870289
pmcid: 4418873
doi: 10.1073/pnas.1418955112
Farino, Z. J. et al. New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion. Mol. Psychiatry 25, 2070–2085 (2020).
pubmed: 30626912
doi: 10.1038/s41380-018-0344-6
Febbraio, M. A. Role of interleukins in obesity: implications for metabolic disease. Trends Endocrinol. Metab. 25, 312–319 (2014).
pubmed: 24698032
doi: 10.1016/j.tem.2014.02.004
Osborn, O. et al. Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity. Cytokine 44, 141–148 (2008).
pubmed: 18723371
pmcid: 3063393
doi: 10.1016/j.cyto.2008.07.004
Barandas, R., Landgraf, D., McCarthy, M. J. & Welsh, D. K. Circadian clocks as modulators of metabolic comorbidity in psychiatric disorders. Curr. Psychiatry Rep. 17, 98 (2015).
pubmed: 26483181
doi: 10.1007/s11920-015-0637-2
Landgraf, D., McCarthy, M. J. & Welsh, D. K. Circadian clock and stress interactions in the molecular biology of psychiatric disorders. Curr. Psychiatry Rep. 16, 483 (2014).
pubmed: 25135782
doi: 10.1007/s11920-014-0483-7
Gabel, K. et al. Effects of 8-hour time restricted feeding on body weight and metabolic disease risk factors in obese adults: a pilot study. Nutr. Healthy Aging 4, 345–353 (2018).
pubmed: 29951594
pmcid: 6004924
doi: 10.3233/NHA-170036
Hutchison, A. T. et al. Time-restricted feeding improves glucose tolerance in men at risk for type 2 diabetes: a randomized crossover trial. Obesity 27, 724–732 (2019).
pubmed: 31002478
Chow, L. S. et al. Time-restricted eating effects on body composition and metabolic measures in humans who are overweight: a feasibility study. Obesity 28, 860–869 (2020).
pubmed: 32270927
doi: 10.1002/oby.22756
Zapata, R. C. & Osborn, O. Susceptibility of male wild type mouse strains to antipsychotic-induced weight gain. Physiol. Behav. 220, 112859 (2020).
pubmed: 32156556
pmcid: 7291782
doi: 10.1016/j.physbeh.2020.112859
Cohrs, S. Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics. CNS Drugs 22, 939–962 (2008).
pubmed: 18840034
doi: 10.2165/00023210-200822110-00004
Gunes, S. & Camkurt, M. A. Sleep-related eating disorder associated with risperidone: an adolescent case. J. Clin. Psychopharmacol. 36, 286–288 (2016).
pubmed: 27035493
doi: 10.1097/JCP.0000000000000502
Lu, M. L. & Shen, W. W. Sleep-related eating disorder induced by risperidone. J. Clin. Psychiatry 65, 273–274 (2004).
pubmed: 15003084
doi: 10.4088/JCP.v65n0220a
Paquet, V., Strul, J., Servais, L., Pelc, I. & Fossion, P. Sleep-related eating disorder induced by olanzapine. J. Clin. Psychiatry 63, 597 (2002).
pubmed: 12143918
doi: 10.4088/JCP.v63n0710d
Horiguchi, J. et al. Nocturnal eating/drinking syndrome and neuroleptic-induced restless legs syndrome. Int. Clin. Psychopharmacol. 14, 33–36 (1999).
pubmed: 10221640
Kobayashi, N. & Takano, M. Aripiprazole-induced sleep-related eating disorder: a case report. J. Med. Case Rep. 12, 91 (2018).
pubmed: 29622043
pmcid: 5885367
doi: 10.1186/s13256-018-1622-2
Cope, M. B. et al. Antipsychotic drug-induced weight gain: development of an animal model. Int. J. Obes. 29, 607–614 (2005).
doi: 10.1038/sj.ijo.0802928
Morgan, A. P. et al. The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse. PLoS One 9, e115225 (2014).
pubmed: 25506936
pmcid: 4266663
doi: 10.1371/journal.pone.0115225
Zapata, R. C. et al. Metabolomic profiles associated with a mouse model of antipsychotic-induced food intake and weight gain. Sci. Rep. 10, 18581 (2020).
pubmed: 33122657
pmcid: 7596057
doi: 10.1038/s41598-020-75624-2
Chaix, A., Zarrinpar, A., Miu, P. & Panda, S. Time-restricted feeding is a preventative and therapeutic intervention against diverse nutritional challenges. Cell Metabol. 20, 991–1005 (2014).
doi: 10.1016/j.cmet.2014.11.001
Kosir, R. et al. Determination of reference genes for circadian studies in different tissues and mouse strains. BMC Mol. Biol. 11, 60 (2010).
pubmed: 20712867
pmcid: 2928770
doi: 10.1186/1471-2199-11-60
Almeida-Oliveira, F., Leandro, J. G. B., Ausina, P., Sola-Penna, M. & Majerowicz, D. Reference genes for quantitative PCR in the adipose tissue of mice with metabolic disease. Biomed. Pharmacother. 88, 948–955 (2017).
pubmed: 28178626
doi: 10.1016/j.biopha.2017.01.091
Li, B. et al. Identification of optimal reference genes for RT-qPCR in the rat hypothalamus and intestine for the study of obesity. Int. J. Obes. 38, 192–197 (2014).
doi: 10.1038/ijo.2013.86
Nakao, R., Okauchi, H., Hashimoto, C., Wada, N. & Oishi, K. Determination of reference genes that are independent of feeding rhythms for circadian studies of mouse metabolic tissues. Mol. Genet. Metab. 121, 190–197 (2017).
pubmed: 28410879
doi: 10.1016/j.ymgme.2017.04.001